# Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

> **NCT02211443** · PHASE1 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 21 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Recombinant full human Anti-EGFR Monoclonal Antibody

## Key facts

- **NCT ID:** NCT02211443
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2015-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211443, "Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02211443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*